To further enhance accessibility, we developed a mini‐program (Figure 7) that allows clinicians to input these key variables—ER status, HER2 status, tumor size, and Path‐score—and instantly calculate ALNM probability, simplifying its application in clinical settings. This evidence concerns the gene ERBB2 and neoplasm.